FDMT Stock Forecast: 4D Molecular Therapeutics, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. hold a median 12-month price target of $28 — +173.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores 4D Molecular Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (72): The shares have been drifting up relative to others.
Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
FDMT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FDMT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +173.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $36 |
| 6 Oct 2026 | Chardan Capital | Maintains | Buy | $26 → $25 |
| 29 Sept 2026 | B of A Securities | Maintains | Buy | $29 → $33 |
| 14 Sept 2026 | Cantor Fitzgerald | Upgrade | Overweight | $20 |
| 31 July 2026 | B. Riley Securities | Initiates | Buy | $37 |
| 20 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $36 |
| 30 Mar 2026 | Jefferies | Assumes | Buy | $40 → $21 |
| 20 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 28 Jan 2026 | Barclays | Initiates | Overweight | — |
| 18 Dec 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | Barclays | Maintains | Overweight | — |
| 11 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 11 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 21 Oct 2025 | RBC Capital | Reiterates | Outperform | — |
| 12 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 12 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 1 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 3 July 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FDMT.
This page is one stock. Monday covers all of them.
FDMT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
FDMT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, 4D Molecular Therapeutics, Inc. returned −1.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
FDMT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 6.0×
- Price / book
- 1.7×
- EV / EBITDA
- —
Cheaper than 18% of US stocks
Cheaper than 49% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −56.7%
- Return on assets
- −31.4%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
4D Molecular Therapeutics, Inc. has a market value of $604.4M and an enterprise value of $335.8M.
Revenue in the twelve months to 30 June 2026: $92.0M. The latest quarter grew 25106.7% year on year.
Net income over the same four quarters: −$179.2M, a −194.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$156.0M.
4D Molecular Therapeutics, Inc. employs 196 people — $469K of revenue per employee.
Data provided by Twelve Data
FDMT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at FDMT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own 4D Molecular Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about FDMT
What is the FDMT stock price forecast for 2026-2027?
The 12 Wall Street analysts covering 4D Molecular Therapeutics, Inc. have a median 12-month price target of $28, with estimates ranging from $18 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is FDMT stock a buy right now?
Of the 12 analysts covering 4D Molecular Therapeutics, Inc., 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 4D Molecular Therapeutics, Inc. 50 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank FDMT?
As at 21 Nov 2026, 4D Molecular Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (72 of 100).
Will FDMT stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +173.7% from the last close, and Ticker Nerd's factor model ranks 4D Molecular Therapeutics, Inc. 50 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the FDMT stock forecast for 2030?
No analyst covering 4D Molecular Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FDMT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $37 over the next 12 months.
How has FDMT stock performed over the past year?
4D Molecular Therapeutics, Inc. returned -1.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does 4D Molecular Therapeutics, Inc. do?
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines built on its proprietary Therapeutic Vector Evolution platform. The company designs customized adeno-associated virus, or AAV, vectors intended to deliver therapeutic payloads to specific tissues and disease areas with precision. Its current clinical development programs are concentrated in retina and pulmonology, reflecting a portfolio aimed at treating serious conditions through targeted gene delivery. In ophthalmology, the company is advancing therapies for retinal vascular diseases and other eye disorders, while its respiratory work includes programs for lung-directed treatment of genetic disease. 4D Molecular Therapeutics, Inc. plays a specialized role in the gene therapy market by combining vector engineering, tissue targeting, and disease-focused development to support next-generation genetic medicine candidates.
CEO Dr. David H. Kirn M.D. · 196 employees · United States · https://www.4dmoleculartherapeutics.com